{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:43:06Z","timestamp":1788291786829,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Academic Emergency Medicine"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Approximately 55,000 patients per year in the United States are exposed to potentially rabid animals and receive rabies postexposure prophylaxis (PEP) and these patients commonly present to the emergency department (ED) for wound care and PEP. Despite the number of rabies exposures seen in EDs each year, there appears to be a knowledge gap among health care providers with regard to prescribing and administering rabies PEP. The following review aims to bridge that knowledge gap by discussing the importance of obtaining a comprehensive exposure history to determine the category of the encounter, the type of animal, and the location of the bite and of consulting outside expert resources to determine whether the rabies PEP series is indicated. In addition, this article will discuss dosing, administration, and schedule of the rabies vaccine and human rabies immune globulin to ensure patients are fully protected from developing rabies. Lastly, this article discusses the potential cost associated with rabies PEP and provides information on managing this barrier.<\/jats:p>","DOI":"10.1111\/acem.14755","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T06:44:58Z","timestamp":1685256298000},"page":"1144-1149","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rabies <scp>postexposure<\/scp> prophylaxis: What the <scp>U.S.<\/scp> emergency medicine provider needs to know"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-4583","authenticated-orcid":false,"given":"Kyle","family":"Gibbons","sequence":"first","affiliation":[{"name":"Critical Care and Emergency Medicine Avera McKennan Hospital and University Heath Center  Sioux Falls South Dakota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Dvoracek","sequence":"additional","affiliation":[{"name":"Critical Care and Emergency Medicine Avera McKennan Hospital and University Heath Center  Sioux Falls South Dakota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Cost of Rabies Prevention.Centers for Disease Control and Prevention.2021. Accessed April 27 2021.https:\/\/www.cdc.gov\/rabies\/location\/usa\/cost.html"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/zph.12514"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2005.227.1912"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.256.2.195"},{"key":"e_1_2_9_6_1","unstructured":"Domestic Animal Surveillance.Centers for Disease Control and Prevention.2020. Accessed December 28 2020.https:\/\/www.cdc.gov\/rabies\/location\/usa\/surveillance\/domestic_animals.html"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.253.12.1555"},{"key":"e_1_2_9_8_1","first-page":"1","article-title":"Human rabies prevention \u2014 United States, 2008 recommendations of the advisory committee on immunization practices","volume":"57","author":"Manning S","year":"2008","journal-title":"MMWR"},{"key":"e_1_2_9_9_1","unstructured":"Use of a Reduced (4\u2010Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies:Recommendations of the Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention.2020. Accessed September 17 2020.https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5902a1.htm"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/313632"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.06.061"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00041-8"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.248.5.505"},{"key":"e_1_2_9_14_1","unstructured":"Vaccines Licensed for Use in the United States.U.S. Food and Drug Administration.2020. Accessed December 29 2020.https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/vaccines\/vaccines\u2010licensed\u2010use\u2010united\u2010states"},{"key":"e_1_2_9_15_1","unstructured":"Rabies Vaccine IMOVAX\u00ae RABIES [package insert]. Sanofi Pasteur SA;2019."},{"key":"e_1_2_9_16_1","unstructured":"RabAvert Rabies Vaccine Rabies Vaccine for Human Use [package insert]. Bavarian Nordic A\/S;2018."},{"key":"e_1_2_9_17_1","unstructured":"HyperRAB [package insert]. Grifols;2019."},{"key":"e_1_2_9_18_1","unstructured":"Rabies Immune Globulin (Human) USP Heat Treated Imogam\u00ae Rabies\u2010HT [package insert]. Sanofi Pasteur SA;2005."},{"key":"e_1_2_9_19_1","unstructured":"KEDRAB Prescribing Information [package insert]. Kamada Ltd.;2017."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.054"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.054"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1627205"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/324087"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655401750174183"},{"key":"e_1_2_9_25_1","unstructured":"Rabies: Adverse Reaction.Centers for Disease Control and Prevention.2020. Accessed October 4 2020.https:\/\/www.cdc.gov\/rabies\/specific_groups\/doctors\/adverse_reaction.html"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X18817143"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.09.013"}],"container-title":["Academic Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acem.14755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T09:22:21Z","timestamp":1699867341000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acem.14755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/acem.14755"],"URL":"https:\/\/doi.org\/10.1111\/acem.14755","archive":["Portico"],"relation":{},"ISSN":["1069-6563","1553-2712"],"issn-type":[{"value":"1069-6563","type":"print"},{"value":"1553-2712","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"2023-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}